ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin和VEGF在乳腺癌组织中的表达及意义

目的 研究乳腺癌组织中ezrin和VEGF蛋白表达与乳腺癌临床因素和预后的关系.方法 应用免疫组化S-P法,检测63例癌组织,20例癌旁组织,30例乳腺良性肿瘤中ezrin和VEGF的表达情况.结果 ezrin和VEGF在乳腺良性肿瘤和乳腺癌癌旁组织中均无异常表达.在乳腺癌组织中,ezrin和VEGF的异常表达率分别为55.56%(35/63)和65.08%(41/63),ezrin和VEGF在乳腺癌中的表达,与其淋巴结转移、临床分期呈正相关,而与无病生存时间呈负相关(P<0.001).ezrin和VEGF在乳腺癌中的表达,与年龄、肿块大小以及月经情况无相关性(P>0.05).结论 检测ezrin和VEGF在乳腺癌中的表达,有助于判断乳腺癌的转移潜能和预后,ezrin可作为乳腺癌淋巴结转移以及判断乳腺癌预后的新指标.     

乳腺癌中ezrin和VEGF的表达及其临床意义

目的:探讨ezrin和VEGF在乳腺癌组织中的表达及其与淋巴细结转移,临床分期以及预后之间的关系.方法: 应用免疫组化S-P方法,检测63例乳腺癌组织ezrin和VEGF的表达.结果: 63例乳腺癌中ezrin和VEGF表达率分别为55.56%(35/63)和65.08%(41/63),ezrin和VEGF在乳腺癌中的表达和淋巴结转移,临床分期呈正相关而和无病生存时间呈负相关(P<0.05).但与年龄、肿块大小以及月经情况无相关性(P>0.05).结论: 检测ezrin和VEGF有助于判断乳腺癌的转移潜能,ezrin有可能成为判断肿瘤预后的新指标.     

围产儿先天性畸形26例报告

降低围产儿病死率是当前加强围产期妇幼保健工作的重要环节。本文根据我院近年来发现围产期死亡病例中先天性畸形病死率比例上升，结合尸检病理所见进行回顾性分析。通过对围产期先天性畸形疾病的研究，为探讨和研究如何减少畸形儿出生，提高我国人口素质，提供一些参考依...     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

乳腺癌中ezrin的表达及临床意义

目的探讨ezrin在乳腺癌组织、癌旁组织以及乳腺良性肿瘤中的表达及临床意义。方法应用免疫组化S—P方法检测63例乳腺癌组织、20例乳腺癌旁组织及30例乳腺良性肿瘤中ezrin的表达情况。结果ezrin在乳腺癌旁组织及乳腺良性肿瘤中均无异常表达;在浸润性乳腺癌组织中,ezrin的阳性表达率为55．56％（35／63）,并且ezrin阳性表达率随着临床分期的增高和淋巴结转移增多而升高（P〈0．01）。无病生存（DFS）时间不足5年（远处转移）或5年内死亡患者的ezrin阳性表达率明显高于DFS在5年以上的患者（P〈0．01）。ezrin的表达与年龄、肿瘤大小、月经无相关性（P值均〉0．05）。结论检测ezrin有助于对乳腺癌预后的判断,并且它可能成为一个新的乳腺癌治疗的靶点。